Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CDA | P32320 | 6/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17635427 | 1.00 | TK1 (0.33) | TK1LMNASMN1; SMN2CDAALB | |
| SCHEMBL12865604 | 0.89 | — | — | |
| SCHEMBL21560996 | 0.86 | TK1 (0.44) | TK1LMNASMN1; SMN2BLMPMP22 | |
| SCHEMBL19129852 | 0.83 | RNASE1 (0.36) | TK1CDAALBPKM | |
| SCHEMBL17635428 | 0.83 | CDA (0.33) | TK1LMNASMN1; SMN2CDAALB | |
| SCHEMBL19129669 | 0.75 | RNASE1 (0.32) | TK1 | |
| SCHEMBL20857203 | 0.73 | TYMS (0.41) | — | |
| SCHEMBL14140654 | 0.72 | — | — | |
| SCHEMBL13389793 | 0.72 | — | — | |
| SCHEMBL13573838 | 0.72 | TK1 (0.44) | TK1LMNASMN1; SMN2BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039798-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039798-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | SAMHD1, TLR3, MAVS | TK1 156/4885LMNA 2320/4885SMN1; SMN2 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.